Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-HER2 small molecule imaging agent - Affibody

X
Drug Profile

Anti-HER2 small molecule imaging agent - Affibody

Alternative Names: [111In]ABY-025; [68Ga]ABY-025; ABY-002; ABY-025; ABY0125; Anti-HER2 Affibody

Latest Information Update: 06 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affibody; GE Healthcare
  • Developer Affibody; Biomedical Radiation Sciences; Herlev Hospital; Swedish Cancer Society
  • Class Peptide fragments; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III HER2 positive breast cancer
  • Preclinical Gastric cancer; Non-small cell lung cancer; Oesophageal cancer

Most Recent Events

  • 06 Dec 2022 Preclinical trials in Gastric cancer (Diagnosis) in Sweden (IV), prior to December 2022 (Affibody Pipeline, December 2022)
  • 06 Dec 2022 Preclinical trials in Non-small cell lung cancer (Diagnosis) in Sweden (IV), prior to December 2022 (Affibody Pipeline, December 2022)
  • 06 Dec 2022 Preclinical trials in Oesophageal cancer (Diagnosis) in Sweden (IV), prior to December 2022 (Affibody Pipeline, December 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top